The ε4 allele of apolipoprotein E (apoE) is associated with an increased risk of developing Alzheimer's disease (AD). To accurately determine the isoformspecific effects of human apoE on brain functions under physiological and pathological situations, we created mice expressing human apoE4 isoform in place of mouse apoE by utilizing the gene-targeting technique on the embryonic stem cells (knock-in). The homozygous ε4 (4/4) mice correctly expressed human apoE4 in the serum and the brain. The human apoE in the brain was found primarily in the astrocytes as was the mouse apoE in the wild-type (+/+) mice. In the 4/4 mice, the serum cholesterol level was 2.5-fold that of the +/+ littermate controls on a regular diet. This marked elevation was accounted for by an accumulation of very low and low density lipoproteins. In the brains of the 4/4 mice, however, the amounts of total cholesterol and phospholipids were significantly decreased compared with the +/+ littermates. These findings indicate that cholesterol and lipid metabolism is markedly altered in the 4/4 mice. Our human apoE4 knock-in mice will be useful in clarifying the role of apoE in the etiologies of AD and cardiovascular diseases in relation to cholesterol and lipid metabolism.
INTRODUCTION
Apolipoprotein E (apoE) is a constituent of several classes of plasma lipoproteins and plays an important role in the transport of cholesterol and phospholipids among various cells of the body (1) . It serves as the ligand that mediates the uptake of lipoprotein particles into cells via the low density lipoprotein receptor (LDLR) and the LDLR-related protein (LRP). The brain is second next to the liver in the content of apoE mRNA (2) , which is predominantly synthesized by astrocytes (3, 4) . Although much remains to be clarified about the lipid and lipoprotein metabolism in the brain, recent studies have revealed that apoE is present in high density lipoprotein (HDL)-like lipoprotein particles in the cerebrospinal fluid (CSF) (5) (6) (7) .
Human apoE is a 299 amino acid protein that occurs in three major isoforms (apoE2, apoE3 and apoE4) encoded by three APOE alleles (ε2, ε3 and ε4) differing with respect to the presence of cysteine or arginine at two polymorphic sites. ApoE3, the most common isoform, has cysteine at amino acid position 112 and arginine at 158; apoE2 has cysteine at both 112 and 158, and apoE4 has arginine at both sites (1) . Numerous epidemiologic studies have established that the ε4 allele is associated with an increased risk of developing both familial late-onset and sporadic Alzheimer's disease (AD) (8) (9) (10) . ApoE immunoreactivity has been detected in senile plaques (11) and neurofibrillary tangles (NFTs) (12) , the two hallmarks of AD. Increased plaques have been found in the brains of ε4 homozygotes (13, 14) . Studies have reported binding of apoE to amyloid β-peptide (Aβ) (8, 15, 16) and to tau protein (17) , the principal constituent of NFTs.
ApoE was originally identified as a 37 kDa protein associated with regenerating nerves (18) , and better defined in later studies on crushed sciatic nerves (19) (20) (21) and lesioned brain (22, 23) . Following brain injury, synthesis of apoE by astrocytes is upregulated, and it is considered to play important roles in the mobilization and redistribution of cholesterol and phospholipids during membrane remodeling (24) . Under these conditions of increased cholesterol availability, cholesterol synthesis is repressed both in the peripheral nerve (25) and the brain (23) .
The cholesterol content of the brain decreases with age (26) , and even further in AD (27) . Recent studies with cultured cells implicate cholesterol-rich membrane microdomains in processing of the amyloid precursor protein (APP) (see below). Interestingly, a recent work showed that apoE4 induces neuronal cell death under conditions of suppressed cholesterol synthesis (28) , suggesting that apoE4 may possibly be less efficient than apoE3 in reparative function in the brain under compromised cholesterol supply. Thus, cholesterol is an intriguing possible link between apoE and AD etiology.
When allele-specific differences in apoE function need to be identified in vivo, it is desirable to have mouse lines in which the murine apoE is replaced by human apoE isoforms expressed under the natural regulation of this protein. Thus, Sullivan et al. (29, 30) produced human apoE3 and apoE2 knock-in mouse lines, and most recently succeeded in apoE4 mice (31) . The E4 homozygotes were found to have plasma cholesterol levels similar to the E3 mice, whereas E2 mice exhibited hypercholesterolemia. We independently undertook generation of human apoE knock-in mice, using a different construct design of targeting vector. Our E4 homozygous mice exhibit an elevated serum cholesterol level compared with the wild-type mice, whereas brain cholesterol content was significantly decreased. This suggests that our human apoE4 knockin mice will provide useful animal models for AD research in relation to cholesterol and lipid metabolism.
RESULTS

Generation of human apoE4 knock-in mice
The 'knock-in' gene-targeting vector was designed to replace all of the mouse Apoe coding sequences including part of exon 2, entire exon 3 and most of exon 4, with the human apoE4 cDNA (Fig. 1A) . To retain normal mouse Apoe regulatory sequences as much as possible, the translation initiation codon of the human apoE4 cDNA in the knock-in allele was placed at the same position as that of the mouse Apoe in the wild-type locus. Thus, non-coding mouse sequences including exon 1, intron 1 and the first 18 bp of exon 2 were retained in the knock-in allele (see Materials and Methods).
The knock-in construct was introduced into E14TG2aIV embryonic stem (ES) cells (32) by electroporation, and cell clones were selected by growth in media containing G418/ gancyclovir. Drug-resistant ES clones were screened for homologous recombination by Southern blot hybridization using 3′ flanking sequences outside the gene-targeting vector, exon 4 or neo probes (data not shown). We identified 7 of 125 G418/gancyclovir-resistant ES clones as having the correct insertion, and two clones (#129 and #145) were used for further studies. In these knock-in ES cells, human apoE immunoreactivity could be demonstrated by western blotting the cell lysates with monoclonal antibody (mAb) 868E5 (see below), whereas mouse apoE was detected both in wild-type and knock-in ES cells with mAb 874B7 (data not shown).
The two independently targeted ES cell clones were injected into C57BL/6N blastocysts, and chimeric mice were generated. Male chimeric mice were mated with C57BL/6N females to produce heterozygous (4/+) mice. The knock-in allele was transmitted to four of seven agouti coat color offspring derived from the #129 ES cell clone (data not shown). The heterozygous (4/+) mice in the F 2 generation were crossed, and produced litters of normal size with a normal Mendelian segregation pattern of the knock-in allele. Genotypes of F 3 generation mice were determined using Southern blot analysis of tail-tip DNA digested with HindIII (Fig. 1B) . The results reported here were obtained with F 3 generation animals of mouse line TgH(HAPE4)129. The amino acid sequence of the entire transgene product was confirmed to be that of the correct human apoE4 (33, 34) by cDNA cloning and sequencing of human apoE mRNA from the liver of a transgenic mouse of this line.
Expression of human apoE4 from the knock-in allele
To examine the expression of human apoE4 from the knock-in allele, sera from the 4/4, 4/+ and +/+ mice were analyzed by western blot analysis ( Fig. 2A) . Human apoE4 protein was detected with human apoE-specific rat mAb 868E5 (35) in sera of the 4/4 and 4/+ mice at the same 37 kDa position as in a control human serum ( Fig. 2A, upper panel) . Western blot analysis with mouse apoE-specific hamster mAb 874B7 (35) showed that mouse apoE was present only in the 4/+ and +/+ and not in the 4/4 mice ( Fig. 2A, lower panel) , indicating that the mouse Apoe coding sequence was completely replaced in the 4/4 mice. Although we cannot precisely compare the amount of human and mouse apoE proteins on western blots due to the likely difference in the affinity of antibodies, it seemed that the level of human apoE4 in the serum of the 4/4 mice was comparable to that of mouse apoE in the wild-type mice. We further showed that apoE in the knock-in mice was recognized by anti-apoE4 specific antibody Ab 412-1-12-2 which binds an apoE4-specific epitope (36) (Fig. 2B ).
In these experiments the extent of sialylation of apoE, as estimated from the characteristic upper bands (5), seems to be less in the mouse than in the human ( Fig. 2A) . The possibility that the sialylation of apoE is differently regulated in the two species remains to be studied.
We next examined the expression of human apoE4 in the brains of the knock-in mouse. Western blotting experiments showed that the human apoE of 37 kDa was expressed in the 4/4 and 4/+ mouse brains (Fig. 2C ). Histological pattern of apoE expression was then studied by immunohistochemistry on frozen sections of paraformaldehyde-fixed brains of the three genotypes (Fig. 3) . Human apoE was detected in the astrocytes and neuropil in the hippocampus (Fig. 3A) and neocortex of the 4/4 mice, where no immunoreactivity for mouse apoE was detectable (Fig. 3B) . No clear apoE immunoreactivity was seen over neuronal somata, although the fluorescence microscopy could not rule out a weak staining of neuronal processes in addition to astrocytic processes in the neuropil. This pattern of apoE staining was similar to the distribution of mouse apoE in the +/+ mouse brain (Fig. 3F) . Heterozygous brains showed staining of both human and mouse apoEs with intermediate intensity (Fig. 3C and D) . Thus the expression of the human apoE protein in our knock-in mice is apparently under the endogenous regulatory control.
Lipid and lipoprotein phenotypes
As an initial step in studying the functional impact of expression of human apoE protein, the levels of total cholesterol (TC) and triglycerides (TG) in the 4/4, 4/+, +/+ and apoE-deficient (-/-) (37) mice were analyzed in the sera obtained after a 6 h fast (Table  1) . Serum TC level in the 4/4 mice (251 ± 23 mg/dl) was 2.5-fold greater than that in the +/+ mice (101 ± 8 mg/dl), but still much lower than in the -/-mice (697 ± 60 mg/dl). Males showed higher TC levels than females: 289 mg/dl versus 212 for 4/4 mice, and 115 versus 87 for +/+ mice (n = 3 each). In the 4/+ mice, serum TC levels were slightly lower than in the +/+ mice. There was no significant difference in TG levels among the 4/4, 4/+ and +/+ mice. Similar results have been obtained for another independent knock-in line TgH(HAPE4)145. For this line TC was 234 mg/dl for 4/4 compared with 131 for +/+ (n = 5 each). The nature of elevated serum TC levels was further studied by analyzing lipoprotein profiles by fast protein liquid chromatography (FPLC) fractionation. As shown in Figure 4A and B, the main cholesterol carrier in serum was HDL (fractions [17] [18] [19] [20] [21] [22] [23] [24] [25] in the +/+ and 4/+ mice. In the 4/4 mice, however, 60% of TC was found in regions corresponding to the VLDL and LDL (fractions 1-16) (Fig. 4C) .
The distribution of apoE was analyzed by western blot analysis of the FPLC fractions (Fig. 4, lower panels) . In the +/+ and 4/+ mice, the mouse apoE was mostly found in the HDL (fractions [17] [18] [19] [20] [21] [22] [23] [24] [25] and also LDL (fractions 10-16) regions with only a minor portion showing up in the VLDL region (fractions 6 and 7). The distribution pattern of human apoE4 in the 4/+ mice was very similar to that of mouse apoE in the +/+ and 4/+ mice. In contrast, the majority of apoE was present in the VLDL and LDL regions with two peaks at fractions 6-7 and 12-13 in the 4/4 mice, in addition to the presence in the HDL region. On western blot analysis with anti-mouse apoE, three discrete bands of 34, 36 and 39 kDa were detected. The relative abundance of the three molecular species appeared to vary with fractions: the 39 kDa species was relatively more abundant in the VLDL, the 36 kDa species in the LDL and the 34 kDa species in the HDL regions. With the anti-human apoE antibody, all fractions displayed the 37 kDa band accompanied by a weak low molecular weight band, a likely partial degradation fragment (38) (Fig. 4B and C) . As the serum cholesterol level was markedly elevated in the 4/4 knock-in mice, it was of particular interest to examine the brain lipids. The brain size was not significantly different among mice of 4/4, 4/+ and +/+ genotypes. Total cholesterol level of the whole brain, however, was reduced by >30% in the 4/4 brain compared with the +/+ brain ( Table 2) . A less pronounced reduction in TC was also observed in the brains of the heterozygotes. A significant reduction in the brain phospholipid content was also found in the 4/4 mice, but not in the heterozygotes.
No difference in gross morphology of the brain was apparent among the 4/4, 4/+ and +/+ mice. No significant difference was noted among the three genotypes in a preliminary histological survey, in which brain sections from 3-month-old mice were stained by thionin or by antibodies specific to GFAP (astrocyte marker), VAMP-2 (synapse marker) or mouse apoJ. A more thorough study is needed to establish absence of altered anatomical phenotype in the knock-in brains.
DISCUSSION
We have produced a line of human apoE4 knock-in mice in which the expression of human apoE4 is under the control of the enhancer/promoter of endogenous mouse Apoe gene, and 
Genotype
Total cholesterol mg/dl (n) Triglycerides mg/dl (n) 4/4 251 ± 23 (6) a 27 ± 4 (6) 4/+ 75 ± 4 (7) b 21 ± 2 (7)
mouse apoE expression was completely eliminated. In these mice, serum cholesterol level was 2.5 times that of the +/+ littermate controls. This marked elevation of serum cholesterol was shown to be primarily due to an accumulation of very low and low density lipoproteins. The brains of 4/4 mice had significantly reduced total cholesterol and phospholipids compared with the littermate controls.
Transgenic mouse models
A number of research groups have in the past produced mice expressing human apoE isoforms instead of the mouse protein through pronuclear injection of human apoE cDNAs placed under various heterologous promoters, and breeding with the apoE-deficient (knock-out) lines generated earlier to eliminate the mouse protein (39) (40) (41) . In this type of transgenic mouse generally, the levels and patterns of transgene expression vary from line to line due to differences in the chromosomal integration sites with unavoidable position effects as well as uncontrollable copy numbers of inserted transgenes. Thus, no two lines can be precisely matched for studying subtle isoform differences. Moreover, expression of apoE in cell types other than the natural expressers through use of heterologous promoters may not provide a valid model animal for AD research. GFAP promoter has been used by some to direct expression of human apoE to astrocytes (39, 40) . However, the expression pattern of apoE in the normal mouse brain does not exactly coincide with that of GFAP (35) . Expected absence of apoE in the periphery in such mice should cause disturbances in the systemic lipid metabolism (42, 43) 
that may have indirect consequences in the central nervous system (CNS).
A most desirable approach, therefore, is to place the transgene expression under the control of endogenous regulatory elements. Xu et al. (44) introduced large segments of human genomic DNA encompassing the APOE locus with attendant human regulatory regions, but the fact that the transgene constructs did not match precisely among the three apoE alleles, combined with uncontrolled integration loci and copy numbers, renders interpretation of results subject to ambiguity.
Sullivan et al. (29, 30) pioneered the generation of human apoE3 and apoE2 mice, and Knouff et al. (31) recently reported their apoE4 mice. They took advantage of homologous recombination to replace a segment of DNA at the Apoe locus with homologous segments of human genomic DNA. The plasma TC level of their E4 homozygotes was not significantly different from that of E3 homozygotes. We used a targeting vector of different design employing human apoE cDNA coding region flanked by appropriate murine genomic DNAs (Fig. 1A) .
Hypercholesterolemia in the apoE4 knock-in mice
Our homozygous apoE4 mice displayed marked hypercholesterolemia (249%) compared with the wild-type littermates (Table 1) . Preliminary results with our E3 homozygotes of F 3 generation indicated that their average TC value is 125 mg/dl (n = 6) compared with 93 mg/dl (n = 5) for their wild-type littermates, indicating that the hypercholesterolemia of E4 mice is an allele-specific phenotype. The apparent discrepancy in the cholesterol phenotype between Knouff et al.'s E4 mice and ours is not likely due to a difference in the fat or cholesterol content of the mouse diet, because a high fat chow did not differentiate cholesterol phenotypes of Knouff et al.'s E4 and E3 mice (31) . Nevertheless, a possibility cannot be excluded that some other component of the diet may have contributed to the discrepancy. This can be tested by exchanging mice or diets. The difference in the construction of transgenes may also be responsible. The Apoe/APOE gene of our knock-in mice lacks introns 2 and 3, whereas Knouff et al.'s mice (31) carry a chimeric intron 1 and human introns 2 and 3, possibly leading to a subtle difference in the regulation of apoE expression. This could be tested by careful comparative analyses of apoE protein expression.
Our analysis of lipoprotein profile (Fig. 4) showed a large increase in VLDL-and LDL-cholesterol without significant changes in the HDL-cholesterol. Interestingly in the humans also, ε4 carriers have increased plasma cholesterol and LDL (45, 46) . ApoE4 has been shown to distribute relatively preferentially to VLDL rather than HDL when compared with apoE3 (47, 48) . A higher catabolic rate of apoE4-bearing VLDL (49) has been offered as an explanation of higher plasma cholesterol levels observed among human ε4 carriers (45) . In this explanation apoE4-bearing VLDL delivers cholesterol more efficiently to the liver, and also accelerates the conversion of VLDL remnants to LDL driving its accumulation. Both will lead to a down-regulation of LDL receptor and further accumulation of LDL. It is tempting to speculate that a similar mechanism may operate in our 4/4 mice.
Brain cholesterol
As a first step toward understanding the physiological and pathological roles of apoE, brain lipids were measured in our apoE4 mice. In contrast to the serum, the homozygote brain showed 32% reduction in total cholesterol, and 17% reduction in phospholipids, when compared with the wild-type littermates. These measurements mostly reflect cell-associated lipids rather than lipoproteins in the interstitial fluid, and thus do not necessarily contradict the elevated cholesterol level found in the serum. Nonetheless, it raises a possibility that the mechanisms of brain parenchymal cholesterol metabolism and traffic may be substantially different from those on the other side of the blood-brain barrier. In fact, apoE and apoAI are the major apolipoproteins, but apoB is not found, in the CNS (5), and LRP is considered to be an important apoE receptor in the brain in addition to the LDL receptor (13) . The decreased brain cholesterol content of the E4 knock-in mice is not likely to be the consequence of interspecies inconsistency between the human apoE and the murine apoE receptors in the brain, since our preliminary results indicate that the brain cholesterol content of our apoE3 knock-in mice is not significantly different from that of wild-type littermates. An interesting possibility would be some property peculiar to the apoE4 protein, such as a hypothetical ability to extract cholesterol from myelin more efficiently, that manifests itself primarily in the CNS tissues. Published studies of human apoE knock-in mice by were devoted to hematologic and vascular studies, and to our knowledge no data are available for comparison regarding their brain cholesterol levels.
The reduced cholesterol content in the brains of apoE4 knock-in mice is particularly intriguing because of recent recognition that Aβ can be detected in association with cholesterol-rich membrane microdomains (50, 51) , and that cholesterol availability affects APP processing in cultured cells (52) (53) (54) (55) (56) (57) and in the brain (58) . Contents of cholesterol and other lipids have been found to be decreased in AD brains (27) . Whether this is the result of degenerative loss of synapses and cells, or it has etiological significance remains to be studied. Much more needs to be learned about cholesterol metabolism in aging and AD brains. A more detailed analysis of cholesterol and other lipids in the brains of our apoE4 mice is also urgent, as well as analyses of APP metabolism there. Equally awaited is the study of doubly transgenic mice to be produced by breeding the apoE 'humanized' lines of mice with the APPoverexpressing transgenic lines that develop pathological changes (59, 60) and to determine how human apoE isoforms differentially affect Aβ production and deposition in the brain.
Dynamic up-regulation of apoE expression after physical injury has long been known in the peripheral nervous system and CNS (19, 21, 22) . More recent studies on experimental ischemia (61), head injury in humans (62) and brain lesions in apoE-deficient mice (63) further support the idea that apoE plays a part in neural repair processes. Perhaps this is a reflection of increased importance of cholesterol recycling in the brain parenchyma, which does not have ready access to the cholesterol in general circulation (64) . Since AD entails sporadic neuronal deaths during characteristically protracted course of the disease, small differences among apoE isoforms in the efficiency of cholesterol transport could have substantial cumulative effects on the timing of clinical onset of AD. Such a possibility could be tested by comparing apoE3 and apoE4 mice with respect to their reactions to one-time and synchronous neuronal insults such as caused by neurotoxin administration (65) or appropriate surgical lesion experiments (66) . Our mice may be useful also in testing the involvement of apoE in neuronal plasticity (24, 67) .
It is hoped that the apoE4 mice reported here will be useful in producing relevant animal models not only for atherosclerosis research but also for clarifying the precise role of apoE in the etiology of AD, and developing effective measures to halt the progression of the disease.
MATERIALS AND METHODS
Mice
Mice of C57BL/6N strain were obtained from Japan Clea (Tokyo, Japan). ApoE-deficient mice of C57BL/6J-Apoe tm1Unc (37) were obtained from the Jackson Laboratory (Bar Harbor, ME). All mice were reared on a normal diet of MF (Oriental Yeast, Chiba, Japan) containing 4.9% fat, 0.075% cholesterol, 23.8% protein, 6.2% ash and 2.7% fiber.
Construction of targeting vector
The targeting construct was made by two-step ligations of DNA fragments. First, a 6.0 kb fragment including mouse Apoe gene 5′ flanking region, exon 1, intron 1 and the first 18 bp of exon 2 (strain 129/SvJ), a human apoE4 cDNA fragment corresponding to nucleotides -59 to +1027 (68) , and a loxP-PGK-neo-loxP (69) fragment were ligated and subcloned into pBluescript II SK (pTG1). The human apoE4 cDNA originated from pKCRHAPE (Japan patent 1985) , a vector for expression of human apoE3. A 280bp Eco47III-SacII fragment was excised from pKCRHAPE and subcloned into pBluescript. A point mutation resulting in Cys112→Arg substitution was introduced by a Pfu DNA polymerase-based mutagenesis using a QuikChange site-directed mutagenesis kit (Stratagene, La Jolla, CA) with a pair of mutagenic primers (E34F, 5′-ACATGGAG-GACGTGCGCGGCCGCCTGGTG-3′; E34R, 5′-CACCAG-GCGGCCGCGCACGTCCTCCATG-3′). The desired point mutation and the entire coding sequences were confirmed by DNA sequence analysis. Next, a 9.0 kb fragment excised from pTG1 and a 2.6 kb fragment of mouse Apoe gene 3′ flanking region were inserted into an F3 vector, which includes a thymidine kinase gene driven by the promoter of pMC1neo (70), giving rise to the targeting vector, pTG2.
Generation of homozygous human apoE4 knock-in mice
The targeting vector, pTG2, was linearlized with SalI and electroporated into ES cells, E14TG2aIV (32) , at 1000 V with a capacitance of 3 µF using a Bio-Rad (Hercules, CA) Gene Pulsar. After double selection with G418 (175 µg/ml) and gancyclovir (2 µM), 125 resistant clones were picked, among which seven targeted ES cell clones were identified by Southern blot analysis. The targeted ES cells were injected into C57BL/6N blastocysts, which were then implanted into the pseudopregnant recipients to produce chimeric mice. Chimeric male mice were mated to C57BL/6N females to examime germ-line transmission of the transgene. The agouti coat color male offspring, which were heterozygous for the human apoE4, were mated to C57BL/6N females to produce the F 2 generation. Mice heterozygous for the human apoE4 in the F 2 generation were intercrossed to generate homozygous human apoE4 knock-in mice. Wild-type littermates from these crosses were used as controls. The floxed neo in the transgene has not been eliminated from the knock-in mice described in this work.
Genomic Southern blot analysis
ES cell DNA was isolated by digesting cells in lysis buffer A (0.2% SDS, 100 µg/ml of proteinase K, 200 mM NaCl, 100 mM Tris pH7.5, 5 mM EDTA) at 55°C overnight and dissolved with TE buffer after ethanol precipitation. Tail-tip DNA was isolated by digesting tail-tip clippings in lysis buffer B (1% SDS, 2 mg/ml proteinase K, 100 mM NaCl, 50 mM Tris pH 8.0, 100 mM EDTA) at 55°C overnight, and dissolved with TE after phenol extraction, chloroform extraction and ethanol precipitation. Genomic DNAs were digested with HindIII, analyzed by electrophoresis, and transferred to the nylon membrane. Transferred DNA was hybridized in hybridization buffer (7% SDS, 50% formamide, 5× SSC, 2% blocking reagent, 50 mM sodium phosphate pH 7.0, 0.1% N-lauroylsarcosine) overnight at 42°C to a DIG-labelled 1.1 kb probe, corresponding to the XmnI-NcoI fragment in the 3′ flanking region shown in Figure 1 . The hybridized membrane was washed twice for 15 min at 68°C with 0.1× SSC, 0.1% SDS, and subsequently incubated with Fab fragments of anti-DIG antibody conjugated with alkaline phosphatase. The chemiluminescence signal was detected using CSPD (Roche Molecular Biochemicals, Mannheim, Germany).
To clone the human apoE4 cDNA from the knock-in mice, poly(A) + RNA was isolated from the liver, and first-strand cDNA was synthesized using SuperScript Preamplification System (Gibco BRL, Rockville, MD). The human apoE4 cDNA was amplified by PCR using oligonucleotides MF (CAATTGGGAA-GATGAAGGTTCTGTGGGCTG) and TR (CGGCGTTCAGT-GATTGTCGCTGGGCACAGG). The PCR fragment of the expected size was cloned into pGEM-T-Easy Vector (Promega, Madison, WI), and sequenced to confirm the absence of inadvertent mutations in the expressed transgene.
Western blot analysis
Human serum (0.5 µl) or mouse fasted sera (1 µl) were combined with 10 µl of SDS-PAGE sample buffer (2.3% SDS, 5% 2-mercaptoethanol, 10% glycerol, 62.5 mM Tris-HCl buffer, pH 6.8) and boiled for 3 min. Whole brains were homogenized in 2 ml of homogenization buffer (5 mM EDTA, 1 mM PMSF, 10 µM leupeptin, 10 µM pepstatin A, 150 mM NaCl, 10 mM sodium phosphate pH 7.2) in a glass-Teflon Potter homogenizer. Aliquots of the homogenate containing 50 µg protein were dissolved with 10 µl of SDS-PAGE sample buffer and boiled for 3 min. The samples were separated by 10% acrylamide SDS-PAGE, and transferred to PVDF membrane. The blots were blocked with 3% non-fat dried milk/phosphate-buffered saline, and incubated for 1 h at room temperature with the primary antibodies: rat monoclonal 868E5 (35) , hamster monoclonal 874B7 (35) or mouse monoclonal Ab 412-1-7 (36) followed by washing and appropriate biotinylated secondary antibodies. The signal was detected by using Vectastain ABC kit (Vector, Burlingame, CA) combined with either chloronaphthol as chromogen or enhanced chemiluminescence (Pierce, Rockford, IL).
Lipid and lipoprotein analysis
Three or four mice of each sex of each genotype (10 weeks) were fasted for 6 h, and blood was collected from abdominal vena cava under Nembutal anesthesia. Brains were removed immediately after exsanguination, and frozen on dry ice. Chloroform-methanol (1:1) extracts of the brains were dried under nitrogen gas and re-extracted with choloform-methanol (2:1). The lower phase was evaporated and extracted with isopropanol for analyses. Levels of total serum cholesterol and triglyceride were determined using enzymatic assay kits, Determiner TC555 and Determiner TGS555 (Kyowa Medex, Tokyo, Japan), respectively. For FPLC size fractionation, 50 µl of mouse serum was injected onto Superose 6 column (FPLC system; Amersham Pharmacia Biotech, Uppsala, Sweden) and eluted at a constant flow rate of 0.5 ml/min with 1 mM EDTA and 50 mM phosphate buffer. Fractions of 0.5 ml were collected and cholesterol concentrations measured enzymatically, and apoE distribution was studied by western blotting.
Immunohistochemistry
Mice were fixed under deep Nembutal anesthesia by cardiac perfusion with chilled 4% paraformaldehyde in 0.1 M phosphate buffer pH 7.2. Brains were removed, post-fixed overnight in the same fixative at 4°C, and cryoprotected in 20% sucrose/phosphate-buffered saline. Cryostat sections of 13 µm were cut and picked up on glass. The sections were exposed overnight either to hamster mAb 884F11 (35) 
